Aligos Therapeutics Inc. (ALGS)
4.21
0.13 (3.19%)
At close: Apr 14, 2025, 1:00 PM
3.19% (1D)
| Bid | 4.15 |
| Market Cap | 25.74M |
| Revenue (ttm) | 3.94M |
| Net Income (ttm) | -131.21M |
| EPS (ttm) | -20.94 |
| PE Ratio (ttm) | -0.2 |
| Forward PE | -1.9 |
| Analyst | Buy |
| Ask | 4.32 |
| Volume | 53,774 |
| Avg. Volume (20D) | 216,773 |
| Open | 4.28 |
| Previous Close | 4.08 |
| Day's Range | 4.15 - 4.47 |
| 52-Week Range | 3.76 - 46.80 |
| Beta | 2.72 |
About ALGS
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The com...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2020
Employees 70
Stock Exchange NASDAQ
Ticker Symbol ALGS
Website https://www.aligos.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ALGS stock is "Buy." The 12-month stock price forecast is $70, which is an increase of 1562.71% from the latest price.
Stock ForecastsNext Earnings Release
Aligos Therapeutics Inc. is scheduled to release its earnings on May 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-19.55%
Aligos Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
2 months ago
-19.25%
Aligos Therapeutics shares are trading lower after the company announced a $105 million private placement financing round.
